Apixaban is NOT appropriate for VTE prophylaxis in an elderly, bedridden patient with hip fracture who is on chronic hemodialysis
Use fondaparinux or low molecular weight heparin (LMWH) instead, as these are the guideline-recommended agents for hip fracture VTE prophylaxis, and apixaban is contraindicated in patients on dialysis.
Critical Contraindication in Dialysis Patients
Apixaban is explicitly contraindicated in patients with end-stage renal disease on hemodialysis. The FDA prescribing information specifies that apixaban should be avoided in patients with severe renal impairment (CrCl <15 mL/min), and patients with CrCl <25 mL/min were excluded from clinical trials 1. Patients on chronic hemodialysis have essentially zero creatinine clearance, placing them well below this threshold.
The European Medicines Agency goes further, explicitly contraindicating apixaban in dialysis patients 2. While some retrospective research suggests apixaban may have a favorable profile compared to warfarin in dialysis patients with atrial fibrillation 3, this evidence:
- Addresses a different indication (atrial fibrillation, not VTE prophylaxis)
- Consists only of observational data, not randomized trials
- Does not override FDA labeling and guideline recommendations
Guideline-Recommended Agents for Hip Fracture
For hip fracture VTE prophylaxis specifically, fondaparinux or LMWH are the recommended agents 4. The 2012 Association of Anaesthetists guideline explicitly states: "Fondaparinux or low molecular weight heparins are commonly prescribed" for hip fracture patients 4.
However, fondaparinux is also contraindicated in severe renal insufficiency (CrCl <30 mL/min) and should not be used in dialysis patients 1. This leaves LMWH as the preferred option, though it requires cautious dosing in elderly patients and those with renal dysfunction 1.
Practical Approach for This Patient
Use LMWH with dose adjustment:
- LMWH can be used in dialysis patients with appropriate dose reduction and monitoring
- Administer between 18:00-20:00 to minimize bleeding risk if neuraxial anesthesia is planned 4
- Exercise particular caution given the patient's elderly status and bedbound state 1
Alternative consideration:
- Unfractionated heparin (UFH) 5000 IU subcutaneously three times daily is an alternative that doesn't accumulate in renal failure 1
- UFH may be safer in this population given its shorter half-life and reversibility
Additional Risk Factors in This Patient
This elderly, bedridden patient with hip fracture has multiple compounding VTE risk factors 5:
- Advanced age
- Hip fracture (highest surgical VTE risk)
- Immobility/bedbound status
- Dialysis-associated hypercoagulability
The 37% DVT prevalence and 6% PE prevalence in hip fracture patients 4 makes prophylaxis essential, but the choice must account for the dialysis contraindication.
Why Recent Research Doesn't Change This Recommendation
While a 2022 study showed comparable outcomes between apixaban (Eliquis) and enoxaparin (Lovenox) after hip fracture surgery 6, and a 2026 study suggested DOACs may be alternatives to LMWH 7, these studies excluded dialysis patients. The 2025 study on extended apixaban therapy 8 similarly did not include dialysis patients and addressed a different clinical question (extended treatment after initial therapy).
The bottom line: Apixaban lacks safety data in dialysis patients for any indication, was not studied in this population for hip fracture prophylaxis, and carries explicit regulatory contraindications. Use LMWH with dose adjustment or UFH instead.